275 results
8-K
EX-99.1
EYPT
EyePoint Pharmaceuticals Inc
6 May 24
EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU™ in Non-Proliferative Diabetic Retinopathy
9:25am
SECURITIES LITIGATION ACT OF 1995: To the extent any statements made in this press release deal with information that is not historical … , these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding
8-K
EX-99.2
EYPT
EyePoint Pharmaceuticals Inc
6 May 24
EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU™ in Non-Proliferative Diabetic Retinopathy
9:25am
Reserved. Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act
8-K
EX-99.1
0qm1u
7 Mar 24
EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Developments
7:05am
8-K
EX-99.1
a2hs1cb8f5upbn1nf3
4 Mar 24
EyePoint Pharmaceuticals Announces Appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer
7:01am
8-K
EX-99.2
fmi7zb qgwgck9l
10 Jan 24
Results of Operations and Financial Condition
7:05am
8-K
EX-99.1
3ttsi irg
10 Jan 24
Results of Operations and Financial Condition
7:05am
8-K
EX-99.2
8ls4hdad3v58sn
8 Dec 23
EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock
4:02pm
8-K
EX-99.3
qyo614lg
8 Dec 23
EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock
4:02pm
8-K
EX-99.1
zk1y4qa
8 Dec 23
EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock
4:02pm
8-K
EX-99.2
18utmo3ex63 0k8
7 Dec 23
EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock
6:11pm
8-K
EX-1.1
gsmkwkmc lut
7 Dec 23
EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock
6:11pm
8-K
EX-99.1
vrjnrpa1 6x8sr
7 Dec 23
EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock
6:11pm
8-K
EX-99.2
jsn5xri
4 Dec 23
Other Events
7:05am
8-K
EX-99.1
kva sa8ufv1
4 Dec 23
Other Events
7:05am
8-K
EX-99.1
ik82tqmg 2zcnwfg
9 Nov 23
Other Events
8:00am
8-K
EX-99.1
75tieph 7gjpsl
1 Nov 23
EyePoint Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Corporate Developments
7:05am
8-K
EX-99.1
0ahumad
16 Oct 23
EyePoint Pharmaceuticals Strengthens Board and Executive Leadership Team
7:05am